Evidence map›Paper›PMID 39456810›Full record

ArticleInternational journal of molecular sciences2024

Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR), Growth Differentiation Factor-15 (GDF-15), and Soluble C5b-9 (sC5b-9) Levels Are Significantly Associated with Endothelial Injury Indices in CAR-T Cell Recipients.

Eleni Gavriilaki, Christos Demosthenous, Paschalis Evangelidis, Zoi Bousiou, Ioannis Batsis, Anna Vardi, Despina Mallouri, Eudoxia-Evaggelia Koravou, Nikolaos Spyridis, Alkistis Panteliadou and 9 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Complement system in cancer: friend or foe of immunotherapy.Journal for immunotherapy of cancer · 2026
    Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Eleni GavriilakiBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.ORCID 0000-0002-8883-8208
Christos DemosthenousBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.ORCID 0000-0002-2008-7954
Paschalis EvangelidisSecond Propedeutic Department of Internal Medicine, Hippocration Hospital, Aristotle University of Thessaloniki, 54642 Thessaloniki, Greece.ORCID 0000-0003-1783-5111
Zoi BousiouBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.ORCID 0000-0003-0011-6997
Ioannis BatsisBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Anna VardiBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Despina MallouriBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Eudoxia-Evaggelia KoravouBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Nikolaos SpyridisBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Alkistis PanteliadouBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Georgios KaravalakisBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Marianna MasmanidouBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Tasoula TouloumenidouBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Apostolia PapalexandriBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Christos PoziopoulosDepartment of Hematology, Metropolitan Hospital, 18547 Athens, Greece.
Evangelia YannakiBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Ioanna SakellariBMT Unit, Hematology Department, George Papanicolaou General Hospital, 57010 Thessaloniki, Greece.
Marianna PolitouThrombosis-Bleeding-Transfusion Medicine Postgraduate Studies, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Ioannis PapassotiriouFirst Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.ORCID 0000-0002-2126-3251

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Endothelial injury indices, such as Endothelial Activation and Stress Index (EASIX), modified EASIX (m-EASIX), and simplified EASIX (s-EASIX) scores, have been previously associated with chimeric antigen receptor-T (CAR-T) cell immunotherapy complications. Soluble urokinase-type plasminogen activator receptor (suPAR), growth differentiation factor-15 (GDF-15), and soluble C5b-9 (sC5b-9) have been described as markers of endothelial injury post-hematopoietic stem cell transplantation. In the current study, we examined whether suPAR, GDF-15, and sC5b-9 levels were associated with endothelial injury indices in adult CAR-T cell recipients. The levels of these markers were measured in patients before CAR-T cell infusion and in healthy individuals with immunoenzymatic methods. We studied 45 CAR-T cell recipients and 20 healthy individuals as the control group. SuPAR, GDF-15, and sC5b-9 levels were significantly higher in the patients' group compared to the healthy control group (

Indexed as

BiomarkersGrowth Differentiation Factor 15Receptors, Urokinase Plasminogen ActivatorAdultAgedFemaleHumansImmunotherapy, AdoptiveMaleMiddle AgedBiomarkersGDF15 protein, humanGrowth Differentiation Factor 15Receptors, Urokinase Plasminogen Activatorchimeric antigen receptor-T (CAR-T)complementcytokine release syndrome (CRS)endothelial activation and stress index (EASIX)endothelial dysfunctiongrowth differentiation factor-15 (GDF-15)immune effector cell-associated neurotoxicity syndrome (ICANS)soluble urokinase plasminogen activator receptor (suPAR)

Identifiers

PMID39456810
PMCPMC11507105

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.